Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Pharmaceutical companies announce collaboration on osteoporosis treatment
February 24th, 2005
Nektar Therapeutics (NASDAQ:NKTR) and Zelos Therapeutics Inc. announced a collaboration to develop an inhaleable powder form of Zelos' parathyroid hormone (PTH) analogue, called Ostabolin-C. Zelos is currently developing an injectable form of Ostabolin-C for the treatment of osteoporosis and has completed three phase I clinical trials. The announcement was made at the ninth annual drug delivery partnerships conference in San Diego, California, sponsored by the Institute for International Research. Osteoporosis is a disease characterized by low bone mass and structural deterioration, which can lead to decreased bone strength and an increased...
Source: Women's Health Weekly (2005-02-24)
|
